Changzhou Qianhong Biopharma Co Ltd (SHE:002550) — Market Cap & Net Worth
Market Cap & Net Worth: Changzhou Qianhong Biopharma Co Ltd (002550)
Changzhou Qianhong Biopharma Co Ltd (SHE:002550) has a market capitalization of $1.27 Billion (CN¥8.69 Billion) as of August 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #7754 globally and #1712 in its home market, demonstrating a 0.44% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Changzhou Qianhong Biopharma Co Ltd's stock price CN¥6.79 by its total outstanding shares 1279800000 (1.28 Billion). See Changzhou Qianhong Biopharma Co Ltd (002550) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Changzhou Qianhong Biopharma Co Ltd Market Cap History: 2015 to 2026
Changzhou Qianhong Biopharma Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.66 Billion to $1.27 Billion (0.29% CAGR).
Changzhou Qianhong Biopharma Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Changzhou Qianhong Biopharma Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.94x
Changzhou Qianhong Biopharma Co Ltd's market cap is 0.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.69x
Changzhou Qianhong Biopharma Co Ltd's market cap is 3.69 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.10 Billion | $776.39 Million | $224.46 Million | 1.42x | 4.91x |
| 2017 | $839.80 Million | $1.07 Billion | $183.00 Million | 0.79x | 4.59x |
| 2018 | $596.10 Million | $1.32 Billion | $221.35 Million | 0.45x | 2.69x |
| 2019 | $737.45 Million | $1.68 Billion | $262.56 Million | 0.44x | 2.81x |
| 2020 | $724.38 Million | $1.67 Billion | -$132.02 Million | 0.43x | N/A |
| 2021 | $847.70 Million | $1.87 Billion | $181.08 Million | 0.45x | 4.68x |
| 2022 | $1.12 Billion | $2.30 Billion | $323.41 Million | 0.49x | 3.47x |
| 2023 | $1.08 Billion | $1.81 Billion | $181.86 Million | 0.59x | 5.93x |
| 2024 | $1.16 Billion | $1.53 Billion | $356.03 Million | 0.76x | 3.26x |
| 2025 | $1.47 Billion | $1.57 Billion | $398.80 Million | 0.94x | 3.69x |
Competitor Companies of 002550 by Market Capitalization
Companies near Changzhou Qianhong Biopharma Co Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Changzhou Qianhong Biopharma Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Changzhou Qianhong Biopharma Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Changzhou Qianhong Biopharma Co Ltd's market cap moved from $1.66 Billion to $ 1.27 Billion, with a yearly change of 0.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.27 Billion | -13.61% |
| 2025 | CN¥1.47 Billion | +26.77% |
| 2024 | CN¥1.16 Billion | +7.69% |
| 2023 | CN¥1.08 Billion | -4.03% |
| 2022 | CN¥1.12 Billion | +32.54% |
| 2021 | CN¥847.70 Million | +17.02% |
| 2020 | CN¥724.38 Million | -1.77% |
| 2019 | CN¥737.45 Million | +23.71% |
| 2018 | CN¥596.10 Million | -29.02% |
| 2017 | CN¥839.80 Million | -23.78% |
| 2016 | CN¥1.10 Billion | -33.45% |
| 2015 | CN¥1.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Changzhou Qianhong Biopharma Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.27 Billion USD |
| MoneyControl | $1.27 Billion USD |
| MarketWatch | $1.27 Billion USD |
| marketcap.company | $1.27 Billion USD |
| Reuters | $1.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more